Sign in →

Test Code CA125 CANCER ANTIGEN 125, SERUM

Additional Codes

Software Test Code
Label Text CA125
EPIC LAB155

Performing Laboratory

NorDx Laboratories

Useful For

An aid in the management of cancer patients, particularly in the detection of residual or recurrent ovarian carcinoma in patients who have undergone first-line therapy

 

The measured CA-125 value of a patient’s sample can vary depending on the testing procedure used. CA-125 values determined on patient samples from different manufacturers cannot be directly compared with one another and could be the cause of erroneous medical interpretations.  

Method Name

Electrochemiluminescent Immunoassay (ECLIA) via Roche Diagnostics Instrumentation

Reference Values

< 38 U/mL

Days and Times Test Performed

Monday through Friday

Report Available

1 Day

Specimen Type

Serum

Preferred Container

Serum Separator Tube (SST)

Preferred Volume

Serum: 1 mL (Serum Separator Tube (SST))

Minimum Volume

Serum: 0.5 mL (Serum Separator Tube (SST))

Specimen Collection and Handling

Spin specimen, separate from clot and send refrigerated.

Sample should not be collected on patients receiving therapy with high biotin doses (i.e. >5 mg/day) until at least 8 hours after the last biotin administration.

Specimen Stability Information

Specimen Type: Serum

Frozen: 3 Months

Refrigerated: 5 Days

Must be spun/separated within: 2 Hours

Add On Capable

Yes

Advance Beneficiary Notice Requirements

This test, when ordered on Medicare patients, is subject to the National Coverage Determination (NCD) policies. Please verify that the diagnosis code (ICD code) you have chosen demonstrates medical necessity for the test as documented in the physician’s patient record. The CMS web site is available to assist you with this verification. A properly executed Advance Beneficiary Notice (ABN) must be submitted with the specimen if medical necessity is not demonstrated by the ICD code chosen.

CPT Code Information

CPT Code

CPT Description

CPT Disclaimer
86304 Immunoassay for Tumor Antigen, Quantitative, CA 125  

Keywords

CA 125 (CANCER ANTIGEN 125)

Performing Laboratory Location

NorDx Laboratories

Clinical Significance

No sample should be collected on patients receiving therapy with high biotin doses(i.e. biotin therapy for Multiple Sclerosis or oncology patients; skin, hair and nail supplements, or multivitamins containing > 5 mg/day) until at least 12 hours after the last biotin administration. If unsure, or if the clinical picture does not fit the results please contact the laboratory . We have methods to check for biotin interference as well as for any other interferences and for the accuracy of the results.

Biotin interference would falsely decrease the result of this assay.

LOINC Code Information

10334-1

Acceptable Alternative Container(s)

Plasma Separator Tube (PST)

Red Top Tube